Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial Results



 Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013
                              Financial Results

Investor Conference Call to be held Wednesday, May 8, 2013 at 8:30am EDT

PR Newswire

NEW YORK, May 6, 2013

NEW YORK, May 6, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:
KERX), a biopharmaceutical company focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease, today announced that a conference call will be
held on Wednesday, May 8, 2013 at 8:30 a.m. EDT to discuss results for the
first quarter ended March 31, 2013 and a business outlook for the remainder of
2013. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio
recording of the conference call will be available for replay at
http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release
to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3
clinical program for Zerenex for the treatment of hyperphosphatemia (elevated
phosphate levels) in patients with end-stage renal disease, conducted pursuant
to a Special Protocol Assessment (SPA) agreement with the FDA, and the New
Drug Application filing with the FDA and the Marketing Authorization
Application filing with the EMA are pending submission.  Zerenex is also in
Phase 2 development in the U.S. for the management of phosphorus and iron
deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent
chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco
Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for
marketing approval of ferric citrate in Japan for the treatment of
hyperphosphatemia in patients with chronic kidney disease.  Keryx is
headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement